PER-173-08已完成未知
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiviral Therapies
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2009年2月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16 至 90（—）
入选标准
- •The patient is a man or woman at least 16 years old.
- •The patient has plasma HIV RNA in the selection (determined by the central laboratory)> 1000 copies / mL within 60 days prior to the treatment phase of this study.
- •The patient has had ART treatment and has had a stable ART treatment for> 2 months before selection.
- •The patient has HIV with a documented susceptibility reduced to at least one drug from each of the 3 classes of authorized oral ART (NNRTI + NRTI + PI) as determined by a genotypic / phenotypic resistance report from the central laboratory used for present protocol In cases where the central laboratory resistance sample fails or the results are not consistent with the previous resistance history, patients may be allowed to enroll based on their previous resistance results and the ART regimen history, after discuss it with the Merck Medical Monitor.
- •The patient has had laboratory values outside the normal ranges within 35 days prior to the treatment phase of this study.
- •The patient has a chest x-ray with no signs of active lung disease within 60 days prior to treatment in this study.
- •The potentially fertile patient agrees to use an acceptable method of birth control throughout the study. Acceptable methods of contraception are defined as intrauterine device (IUD), diaphragm with spermicide, condoms or withdrawal.
排除标准
- •The patient does not meet the inclusion criteria for the protocol.
- •The female patient is pregnant or breastfeeding, or is hoping to conceive or donate her eggs during the study. The male patient is planning to fertilize or donate his sperm during the study.
- •The patient has used any investigating agent within the month prior to treatment in this study with the exception of direct ART agents that are available by expanding access, as described in Section I.E.l. Study Design Summary.
- •The patient has used another experimental HIV integrase inhibitor.
- •The patient has used immunosuppressive therapy within the month prior to treatment in this study. Short cycles of corticosteroids will be allowed (for example, as for an asthma exacerbation).
- •The patient requires or is expected to require any of the prohibited medications listed in the protocol.
- •The patient has a current (active) diagnosis of acute hepatitis due to any cause or chronic hepatitis that is not a stable chronic Hepatitis B and / or C.
- •The patient has a history of alcohol or other substance abuse that in the opinion of the investigator could interfere with patient compliance or safety.
- •The patient has any laboratory disorder or anomaly prior to the study, or a history of any disease, which, in the opinion of the researcher, could confuse the results of the study or pose an additional risk when administering the study drugs to the patient.
- •There is the inability to obtain a signed informed consent from a patient 18 years of age or older or when the parent / legal representative has granted consent, there is the inability to obtain the consent of a patient 16 or 17 years of age.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX® as Applicable in Patients with Idiopathic Overactive Bladder with Urinary IncontinencePatients with symptoms of idiopathic overactive bladder (frequency and urgency) and urinary incontinence, whose symptoms have not been adequately managed with anticholinergic therapyMedDRA version: 12.0Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2009-013088-20-NLAllergan Ltd534
进行中（未招募）
1 期
A clinical trial to investigate the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Gastroparesisdiabetic or idiopathic gastroparesis.MedDRA version: 19.0Level: LLTClassification code 10021227Term: Idiopathic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 19.0Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-003250-13-PLTheravance Biopharma R&D, Inc.200
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX® in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivityrinary incontinence due to neurogenic detrusor overactivityMedDRA version: 9.1Level: LLTClassification code 10029279Term: Neurogenic bladderEUCTR2007-000192-42-NLAllergan Ltd260
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-ResponseStudy to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex Injected into the Prostatefor the Treatment of Lower Urinary Tract Symptoms in Patients due to BenignProstatic HyperplasiaPatients with lower urinary tract symptoms due to Benign Prostatic HyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2005-004281-17-ATAllergan Inc.350
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of L-000796568 in Postmenopausal Women With Overactive Bladder - L-000796568 Overactive Bladder StudyOverative BladderMedDRA version: 8.0Level: LLTClassification code 10059617EUCTR2005-004499-19-IEMerck Sharp & Dohme Ireland (Human Health) Limited